NVST vs SLN
Envista Holdings vs Silence Therapeutics plc — AI-powered side-by-side comparison
NVST
Envista Holdings
76
Strong Buy
VS
SLN
Silence Therapeutics plc
48
Watch
| Metric | NVST | SLN |
|---|
| AI Score |
76
|
48
|
| Price |
$28.51
|
$14.69
|
| P/E Ratio |
48.34×
|
-6.72×
|
| ROE |
1.5%
|
-142.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
55.5%
|
68.6%
|
| Debt / Equity |
0.52×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
59.3
|
74.4
|
| Beta |
0.861
|
1.351
|
| Expected Upside |
+1.4%
|
—
|
AI Committee View
Current Innellis committee reasoning for NVST versus SLN.
NVST leads by 28 points.
NVST scores 76/100 (Strong Buy) versus SLN at 48/100 (Watch).
NVST Committee View
100% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- Weekly trend is bearish while daily is bullish — against the higher-timeframe trend.
- Risk/reward is unfavorable: 14.2% downside vs 1.4% upside.
SLN Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -99.3% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -103.3% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 2.02 adds balance-sheet risk to the value case — Value
- Revenue declining -99.3% YoY -- this is not a growth story right now — Growth